BANK VONTOBEL/CALL/NOVO NORDISK ADR B/115/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 18:49:01 27/06/2024 BST | ||
| 2.93 EUR | +1.03% |
|
| Current month | +41.55% | ||
| 1 month | +40.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 2.93 | +1.03% |
| 26/06/24 | 2.9 | -8.23% |
| 25/06/24 | 3.16 | +14.91% |
| 24/06/24 | 2.75 | -0.36% |
| 21/06/24 | 2.76 | +3.76% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 06:49 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM31AB |
| ISIN | DE000VM31AB9 |
| Date issued | 16/10/2023 |
| Strike | 115 $ |
| Maturity | 20/09/2024 (85 Days) |
| Parity | 10 : 1 |
| Emission price | 1.03 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.21 € |
|---|---|
| Lowest since issue | 0.49 € |
| Spread | 0.01 € |
| Spread % | 0.34% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,003
DKK
Average target price
937.9
DKK
Spread / Average Target
-6.45%
- Stock Market
- Warrants
- Warrant
